TriangleNCT04731844 · OUTCOME
Safety and Tolerability of Curcumin in Combination With Piperine
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- participants
- Interval / dispersion
- Not reported
- Time frame
- From start of study treatment through study completion, an average of 1 year for non-serious adverse events; and from screening through study completion, an average of 1 year for serious adverse events.
What was measured
Adverse events were summarized by grade and event type per CTCAE version 5.0. The safety population included all participants who received at least one dose of curcumin plus piperine. Results are presented as the number (percentage) of participants who experienced at least one adverse event.
Analysis population: All enrolled participants
Groups in this outcome
Prostate Cancer
Curcumin plus Piperine at a dose of 2gm/10mg (2 tablets) orally BID for 12 months Curcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.
Smoldering Multiple Myeloma (SMM)
Curcumin plus Piperine at a dose of 2gm/10mg (2 tablets) orally BID for 12 months Curcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.
Monoclonal Gammopathy of Unknown Significance (MGUS)
Curcumin plus Piperine at a dose of 2gm/10mg (2 tablets) orally BID for 12 months Curcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.
| Group | Source count |
|---|---|
| Prostate Cancer | 12 |
| Smoldering Multiple Myeloma (SMM) | 8 |
| Monoclonal Gammopathy of Unknown Significance (MGUS) | 9 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Prostate Cancer | 10 | Not reported | Not reported | Not reported | Not reported |
| Smoldering Multiple Myeloma (SMM) | 7 | Not reported | Not reported | Not reported | Not reported |
| Monoclonal Gammopathy of Unknown Significance (MGUS) | 8 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 10
- group Id
- OG001
- value
- 7
- group Id
- OG002
- value
- 8
- denoms
- counts
- group Id
- OG000
- value
- 12
- group Id
- OG001
- value
- 8
- group Id
- OG002
- value
- 9
- units
- Participants
- description
- Adverse events were summarized by grade and event type per CTCAE version 5.0. The safety population included all participants who received at least one dose of curcumin plus piperine. Results are presented as the number (percentage) of participants who experienced at least one adverse event.
- groups
- description
- Curcumin plus Piperine at a dose of 2gm/10mg (2 tablets) orally BID for 12 months Curcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.
- id
- OG000
- title
- Prostate Cancer
- description
- Curcumin plus Piperine at a dose of 2gm/10mg (2 tablets) orally BID for 12 months Curcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.
- id
- OG001
- title
- Smoldering Multiple Myeloma (SMM)
- description
- Curcumin plus Piperine at a dose of 2gm/10mg (2 tablets) orally BID for 12 months Curcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.
- id
- OG002
- title
- Monoclonal Gammopathy of Unknown Significance (MGUS)
- param Type
- NUMBER
- population Description
- All enrolled participants
- reporting Status
- POSTED
- time Frame
- From start of study treatment through study completion, an average of 1 year for non-serious adverse events; and from screening through study completion, an average of 1 year for serious adverse events.
- title
- Safety and Tolerability of Curcumin in Combination With Piperine
- type
- SECONDARY
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice